N-Cyclohexylmethylone (cyputylone) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in the United States in 2022.[2][3]

N-Cyclohexylmethylone
Clinical data
Other namesCybutylone
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class B
  • US: Unscheduled, schedule I in Virginia[1]
Identifiers
  • 1-(Benzo[d][1,3]dioxol-5-yl)-2-(cyclohexylamino)propan-1-one
PubChem CID
UNII
Chemical and physical data
FormulaC16H21NO3
Molar mass275.348 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC2=C(C=C1)OCO2)NC3CCCCC3
  • InChI=1S/C16H21NO3/c1-11(17-13-5-3-2-4-6-13)16(18)12-7-8-14-15(9-12)20-10-19-14/h7-9,11,13,17H,2-6,10H2,1H3
  • Key:WZDQUORQDHVTKD-UHFFFAOYSA-N

See also edit

References edit

  1. ^ "§ 54.1-3446. Schedule I." Virginia Law. Retrieved 14 September 2023.
  2. ^ CFSRE (2022) N-Cyclohexyl methylone
  3. ^ Kuropka P, Zawadzki M, Szpot P (September 2022). "A review of synthetic cathinones emerging in recent years (2019-2022)". Forensic Toxicology. 41 (1): 25–46. doi:10.1007/s11419-022-00639-5. PMC 9476408. PMID 36124107.